🇺🇸 Arnuity Ellipta in United States

FDA authorised Arnuity Ellipta on 20 August 2014

Marketing authorisations

FDA — authorised 20 August 2014

  • Application: NDA205625
  • Marketing authorisation holder: GLAXOSMITHKLINE
  • Local brand name: ARNUITY ELLIPTA
  • Indication: POWDER — INHALATION
  • Status: approved

Read official source →

FDA

  • Status: approved

Arnuity Ellipta in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Arnuity Ellipta approved in United States?

Yes. FDA authorised it on 20 August 2014; FDA has authorised it.

Who is the marketing authorisation holder for Arnuity Ellipta in United States?

GLAXOSMITHKLINE holds the US marketing authorisation.